Search clinical trials for: CC-99282

Total 834 results

Celgene

Active, not recruiting

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Multiple Myeloma

United States, Canada, Japan, Puerto Rico
Actavis Inc.

Completed

A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions

Healthy

United States
Kathleen Dorritie
Bristol-Myers Squibb

Recruiting

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Celgene

Completed

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Leukemia, Myeloid, Acute

Korea, Republic of, Australia
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

Plaque Psoriasis
University of British Columbia

Completed

Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin

Alopecia Areata

Canada
T.C. ORDU ÜNİVERSİTESİ

Completed

Comparison of Two Regional Technics In Knee Artroplasty (CTRTIKA)

Anesthesia; Functional | Postoperative Analgesia
M.D. Anderson Cancer Center
Yukiguni Maitake Company Ltd.

Terminated

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Advanced Cancers

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Healthy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Leukemia | Plasma Cell Myeloma | B-Cell Non-Hodgkin Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

Plaque Psoriasis

Spain, United States, Canada, Germany, Denmark, France, Italy, Switzerland, Austria
Amgen

Completed

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Psoriasis | Psoriatic Arthritis

United States, Canada, United Kingdom, Australia, Hungary, Belgium, Netherlands, Germany, Czechia, Estonia, Latvia
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

United States, Canada
University of Chicago

Recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))

Multiple Myeloma

United States
Oncotherapeutics

Terminated

Combination Study for High Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Celgene

Completed

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Myelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid Metaplasia

United States, Italy, United Kingdom, Austria, Spain
National Cancer Institute (NCI)

Completed

Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Anemia | Thrombocytopenia | Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
The Catholic University of Korea

Unknown

Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo

Vitiligo | Treatment | Corticosteroid | Intralesional Injection

Korea, Republic of
Steven P. Treon, MD, PhD
Celgene Corporation

Terminated

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Georgetown University
National Cancer Institute (NCI)

Terminated

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions
University of Colorado, Denver

Terminated

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma

United States
University Magna Graecia

Completed

Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome | Anovulation

Italy
Virginia Clinical Research, Inc.
Celgene Corporation

Unknown

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

Lichen Planus

United States
Alice Mims
National Cancer Institute (NCI)

Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditions

United States
Ashraf Badros
Merck Sharp & Dohme LLC

Terminated

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Amgen

Active, not recruiting

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma

United States
Paul Richardson, MD
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts... and other collaborators

Active, not recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

Multiple Myeloma

United States
Celgene

Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (OPTIMISMM)

Multiple Myeloma

United States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
Case Comprehensive Cancer Center

Terminated

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
National Cancer Institute (NCI)

Recruiting

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma

United States
Amsterdam UMC, location VUmc
Celgene

Active, not recruiting

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)

Multiple Myeloma

Netherlands
Fred Hutchinson Cancer Center

Active, not recruiting

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Transplant-Related Carcinoma

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate

United States
Andrei Iagaru
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Celgene
Multiple Myeloma Research Consortium

Completed

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Recurrent Lymphoplasmacytic Lymphoma | AIDS-Related Hodgkin Lymphoma

United States
Celgene

Completed

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Sprint)

Lymphoma, Mantle-Cell | Mantle Cell Lymphoma

France, United Kingdom, Belgium, Spain, Denmark, Germany, Israel, Russian Federation, Italy, Poland, Netherlands, Sweden, Greece, Czechia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant

Acute Myeloid Leukemia

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands

Search clinical trials for: CC-99282

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations